Pasithea Therapeutics Corp. (KTTA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders, RASopathies, and MAPK pathway-driven tumors. The reporting period covers the three and six months ended June 30, 2025. The Company is classified as a Smaller Reporting Company and an Emerging Growth Company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3.72) million | $(7.28) million | $(7.73) million |
| Loss Per Share (Diluted) | $(0.66) | $(1.85) | $(7.41) |
| Cash and Cash Equivalents | $7.22 million (as of June 30, 2025) | $7.22 million | $7.97 million (as of June 30, 2024) |
| Working Capital | $6.90 million | $6.90 million | $6.25 million (as of Dec 31, 2024) |
| Operating Cash Flow | Not provided for 3 months | $(6.92) million | $(8.36) million |
| Financing Cash Flow | Not provided for 3 months | $7.21 million | $0 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately 6.2% year-over-year for the six months ended June 30, 2025, compared to the same period in 2024. This was driven by a reduction in preclinical research and development expenses due to the de-prioritization of discovery programs (PAS-003 and PAS-001), offset by increased clinical trial costs for the lead candidate PAS-004.
- Capital Structure: The Company significantly increased its share count from 1.39 million shares at year-end 2024 to 7.44 million shares as of June 30, 2025. This was due to a May 2025 public offering, exercises of pre-funded warrants, and sales under an At-The-Market (ATM) agreement.
- Other Income: Other income, net, decreased by 18.2% year-over-year for the six-month period, primarily due to lower interest and dividend income, partially offset by gains from foreign currency transactions and changes in the fair value of warrant liabilities.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management states there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the filing date without additional funding. As of June 30, 2025, cash resources are approximately $7.2 million.
- Clinical Progress: The Company is conducting a Phase 1 dose escalation study for PAS-004 in MAPK pathway-driven tumors (expected completion in 2026) and initiated a Phase 1/1b trial for PAS-004 in adult patients with Neurofibromatosis Type 1 (NF1) in May 2025.
- Nasdaq Compliance: On June 23, 2025, the Company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. The Company has 180 days to regain compliance and is considering a reverse stock split.
- Capital Raising: The Company raised approximately $6.3 million in gross proceeds during the first half of 2025 through a public offering, ATM sales, and warrant exercises. Future operations depend on securing additional equity or debt financing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.2 million cash balance against projected burn rates for ongoing clinical trials (PAS-004).
- Nasdaq Status: Monitor the Company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Dilution Impact: Assess the impact of the recent 5x increase in share count (from 1.39M to 7.44M) on future earnings per share and ownership dilution.
- Clinical Milestones: Track enrollment and safety data from the newly initiated Phase 1/1b NF1 trial and the ongoing Phase 1 dose escalation study.
- Debt Obligations: Review the terms of the financed Director and Officer insurance premiums ($155k remaining balance) and any other contingent liabilities.